Director of Medical Analytics and Insights Lead, GlaxoSmithKline plc
Driving Health Care Strategy in the COVID Era
Bilikis Akindele has a broad and diverse health care background with professional roles including medical doctor, informaticist and business leader. She currently serves as a Director of Medical Analytics and Insights Lead at GlaxoSmithKline plc, a multinational company that develops and manufactures pharmaceutical medicines, vaccines and consumer health care products.
In this role, Bilikis works closely with GSK's US Medical Affairs team with focus on the Respiratory Therapy Area. Her work identifies opportunities to leverage data science and synthesis of information from multiple sources - internal and external- with the goal of generating actionable insights. These insights identify gaps in scientific data and unmet medical needs, leading to new solutions and/or actions necessary for delivering the right treatments to the right patients at the right time. Over the past few months, one of Bilikis' priorities has been to synthesize information and generate insights related to the effects of COVID-19 on healthcare systems and the management of patients with various Respiratory diseases especially Asthma and COPD.
In keeping with her multifaceted work history and her focus on linking new knowledge for GSK, Bilikis recently participated in Harvard Medical School's executive program, Driving Health Care Strategy in the COVID Era: Insights from Inside the Ecosystem.
"I was drawn to this program because of its focus on the interconnected nature of the health care ecosystem as evident from the course outline," said Bilikis. "Rather than examining health care through a single lens, I was seeking a learning experience that would give me new perspectives into the array of factors and new entrants, that are shaping the industry right now."
For Bilikis, reflection is an important aspect of the learning process. She appreciated that the program offered ample opportunities weekly to reflect on and scrutinize a wide range of issues including equity in care provision. As a result, she left the program with practical ideas and a refined ‘lens’ that will help GSK craft new solutions and make informed decisions, taking into account the current realities of health care.